Free Trial

Neopharmed Final Terms

CREDIT SUPPLY

FINAL TERMS: Neopharmed Gentili EUR 750mn Sr Sec

EUR 400mn 6NC1 FRN 99.50, 3mE+425 vs. IPT 99.00-99.50, 3mE+450

EUR 350mn 6NC2 Fixed at Par 7.125% vs. IPT Low-mid 7%s

To read the full story

Close

Why MNI

MNI is the leading provider

of intelligence and analysis on the Global Fixed Income, Foreign Exchange and Energy markets. We use an innovative combination of real-time analysis, deep fundamental research and journalism to provide unique and actionable insights for traders and investors. Our "All signal, no noise" approach drives an intelligence service that is succinct and timely, which is highly regarded by our time constrained client base.

Our Head Office is in London with offices in Chicago, Washington and Beijing, as well as an on the ground presence in other major financial centres across the world.